Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis : a multicentre, prospective, observational study
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology..
Objective: We aimed to evaluate quality of life (QoL), disease activity, compliance to treatment, patient and physician preferences for route of administration (RoA), status of health and pain in RA patients starting advanced treatments or needing a switch, and the factors associated with patient preferences.
Methods: A multicentre, prospective, observational and 1-year follow-up study was conducted, between 2015 and 2020, in adult RA patients using advanced treatments for the first time or needing a switch in their current treatments. All the data collected were entered into electronic case report forms. DAS in 28 joints with ESR [DAS28-4(ESR)], EuroQol 5-Dimensional Questionnaire (EQ-5D), HAQ Disability Index (HAQ-DI), Compliance Questionnaire for Rheumatology (CQR-19), Work Productivity and Activity Impairment Instrument (WPAI) and Patient Global Assessment-Visual Analogue Scale (PGA-VAS) questionnaires were used for longitudinal assessments.
Results: Four hundred and fifty-nine patients were enrolled. Three hundred and eight patients (67.1%) attended the final study visit at 12 months and were included for comparative analyses. Irrespective of RoA, the disease activity and QoL improved significantly at 12 months, whereas compliance worsened. At baseline and 12 months, EQ-5D and DAS28-4(ESR) scores were significantly correlated (P < 0.001). The WPAI scores changed significantly in favour of better outcomes over 12 months after initiation of advanced treatment or switching (P < 0.001). A higher proportion of patients preferred an oral RoA, in comparison to physicians (53.6% vs 31.4%; P < 0.001). Patient and physician RoA preferences were independent of gender, age, disease duration, advanced treatment type and the EQ-5D-3L, DAS28-4(ESR), HAQ-DI, PGA-VAS and CQR-19 scores at baseline.
Conclusion: The oral route was more frequently preferred by patients compared with physicians, although patients' preference rates showed a slight increase towards the end of the treatment, which might be an important factor for RA outcomes. Better control of disease activity and QoL were achieved at 12 months, regardless of RoA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Rheumatology advances in practice - 6(2022), 3 vom: 27., Seite rkac071 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Direskeneli, Haner [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Advanced treatment |
|---|
| Anmerkungen: |
Date Revised 24.09.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/rap/rkac071 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346503728 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346503728 | ||
| 003 | DE-627 | ||
| 005 | 20231226031619.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rap/rkac071 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346503728 | ||
| 035 | |a (NLM)36133962 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Direskeneli, Haner |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis |b a multicentre, prospective, observational study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.09.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. | ||
| 520 | |a Objective: We aimed to evaluate quality of life (QoL), disease activity, compliance to treatment, patient and physician preferences for route of administration (RoA), status of health and pain in RA patients starting advanced treatments or needing a switch, and the factors associated with patient preferences | ||
| 520 | |a Methods: A multicentre, prospective, observational and 1-year follow-up study was conducted, between 2015 and 2020, in adult RA patients using advanced treatments for the first time or needing a switch in their current treatments. All the data collected were entered into electronic case report forms. DAS in 28 joints with ESR [DAS28-4(ESR)], EuroQol 5-Dimensional Questionnaire (EQ-5D), HAQ Disability Index (HAQ-DI), Compliance Questionnaire for Rheumatology (CQR-19), Work Productivity and Activity Impairment Instrument (WPAI) and Patient Global Assessment-Visual Analogue Scale (PGA-VAS) questionnaires were used for longitudinal assessments | ||
| 520 | |a Results: Four hundred and fifty-nine patients were enrolled. Three hundred and eight patients (67.1%) attended the final study visit at 12 months and were included for comparative analyses. Irrespective of RoA, the disease activity and QoL improved significantly at 12 months, whereas compliance worsened. At baseline and 12 months, EQ-5D and DAS28-4(ESR) scores were significantly correlated (P < 0.001). The WPAI scores changed significantly in favour of better outcomes over 12 months after initiation of advanced treatment or switching (P < 0.001). A higher proportion of patients preferred an oral RoA, in comparison to physicians (53.6% vs 31.4%; P < 0.001). Patient and physician RoA preferences were independent of gender, age, disease duration, advanced treatment type and the EQ-5D-3L, DAS28-4(ESR), HAQ-DI, PGA-VAS and CQR-19 scores at baseline | ||
| 520 | |a Conclusion: The oral route was more frequently preferred by patients compared with physicians, although patients' preference rates showed a slight increase towards the end of the treatment, which might be an important factor for RA outcomes. Better control of disease activity and QoL were achieved at 12 months, regardless of RoA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DAS | |
| 650 | 4 | |a ESR | |
| 650 | 4 | |a RA | |
| 650 | 4 | |a advanced treatment | |
| 650 | 4 | |a patient preference | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a switch | |
| 700 | 1 | |a Karadag, Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Ates, Askin |e verfasserin |4 aut | |
| 700 | 1 | |a Tufan, Abdurrahman |e verfasserin |4 aut | |
| 700 | 1 | |a Inanc, Nevsun |e verfasserin |4 aut | |
| 700 | 1 | |a Koca, Serdar S |e verfasserin |4 aut | |
| 700 | 1 | |a Cetin, Gozde Y |e verfasserin |4 aut | |
| 700 | 1 | |a Akar, Servet |e verfasserin |4 aut | |
| 700 | 1 | |a Cinar, Muhammet |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Sedat |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Neslihan |e verfasserin |4 aut | |
| 700 | 1 | |a Dalkilic, Ediz |e verfasserin |4 aut | |
| 700 | 1 | |a Bes, Cemal |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmazer, Baris |e verfasserin |4 aut | |
| 700 | 1 | |a Sahin, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Ersözlü, Duygu |e verfasserin |4 aut | |
| 700 | 1 | |a Tezcan, Mehmet E |e verfasserin |4 aut | |
| 700 | 1 | |a Sen, Nesrin |e verfasserin |4 aut | |
| 700 | 1 | |a Keser, Gokhan |e verfasserin |4 aut | |
| 700 | 1 | |a Kalyoncu, Umut |e verfasserin |4 aut | |
| 700 | 1 | |a Armagan, Berkan |e verfasserin |4 aut | |
| 700 | 1 | |a Hacibedel, Basak |e verfasserin |4 aut | |
| 700 | 1 | |a Helvacioglu, Kerem |e verfasserin |4 aut | |
| 700 | 1 | |a Cesur, Teoman Y |e verfasserin |4 aut | |
| 700 | 1 | |a Basibuyuk, Canberk S |e verfasserin |4 aut | |
| 700 | 1 | |a Alkan, Serdar |e verfasserin |4 aut | |
| 700 | 1 | |a Gunay, Levent Mert |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology advances in practice |d 2017 |g 6(2022), 3 vom: 27., Seite rkac071 |w (DE-627)NLM291368786 |x 2514-1775 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2022 |g number:3 |g day:27 |g pages:rkac071 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rap/rkac071 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2022 |e 3 |b 27 |h rkac071 | ||